t
Aptamer Group plc announced on 3 November 2025 that it posted its Annual Report and Accounts for the year ended 30 June 2025 and Notice of its 2025 Annual General Meeting (AGM) to shareholders. The Company will host its AGM at 11:00 GMT on 27 November 2025.
| Date | 3 Nov 2025 |
| Time | 07:00:12 |
| Category | AGMs and other meetings |
| ID | 7690F |
3 November 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Posting of Annual Report and Accounts and Notice of Annual General Meeting
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces that the Annual Report and Accounts for the year ended 30 June 2025 and Notice of its 2025 Annual General Meeting (AGM) were posted to shareholders today. These documents are available on the Company's website at https://aptamergroup.com/.
Aptamer will host its AGM at 11:00 GMT on 27 November 2025 at Windmill House, Innovation Way, York, YO10 5BR. The AGM will be held in person only and there will be no new information presented at the meeting.
The results of voting on all resolutions at the AGM will be announced to the London Stock Exchange and the full results of the voting published on the Company's website, as soon as practicable after the conclusion of the AGM.
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/